In this study, we have characterised the role of androgens specifically DHT, in regulating EV secretion from prostate cancer cells and demonstrate that CD9-enriched EV can modulate cellular proliferation when the availability of androgen is limited as may occur during androgen deprivation therapy. This evidence concerns the gene CD9 and prostate carcinoma.